Trial Profile
A Randomized, Double-blind, Active Control Evaluation of the Safety of BioErodible MucoAdhesive (BEMA) Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 09 May 2017
Price :
$35
*
At a glance
- Drugs Buprenorphine/naloxone (Primary) ; Buprenorphine
- Indications Opioid-related disorders
- Focus Therapeutic Use
- Sponsors BioDelivery Sciences International
- 02 May 2017 Planned End Date changed from 1 Dec 2015 to 1 May 2017.
- 02 May 2017 Planned primary completion date changed from 1 Dec 2015 to 1 May 2017.
- 02 May 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.